ES3053505T3 - Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment - Google Patents
Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatmentInfo
- Publication number
- ES3053505T3 ES3053505T3 ES18823320T ES18823320T ES3053505T3 ES 3053505 T3 ES3053505 T3 ES 3053505T3 ES 18823320 T ES18823320 T ES 18823320T ES 18823320 T ES18823320 T ES 18823320T ES 3053505 T3 ES3053505 T3 ES 3053505T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- compound
- carbon atoms
- cancer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475451P | 2017-03-23 | 2017-03-23 | |
| PCT/US2018/024133 WO2019005241A1 (en) | 2017-03-23 | 2018-03-23 | TRI-SUBSTITUTED IMIDAZOLES FOR INHIBITION OF TGF-BETA AND METHODS OF TREATMENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3053505T3 true ES3053505T3 (en) | 2026-01-22 |
Family
ID=64741862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18823320T Active ES3053505T3 (en) | 2017-03-23 | 2018-03-23 | Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11124509B2 (https=) |
| EP (1) | EP3600294B1 (https=) |
| JP (2) | JP2020512400A (https=) |
| ES (1) | ES3053505T3 (https=) |
| WO (1) | WO2019005241A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11124509B2 (en) | 2017-03-23 | 2021-09-21 | Clavius Pharmaceuticals, LLC. | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment |
| US12077548B2 (en) | 2018-08-22 | 2024-09-03 | Clavius Pharmaceuticals, LLC. | Substituted imidazoles for the inhibition of TGF-β and methods of treatment |
| SG11202104331YA (en) | 2018-12-11 | 2021-05-28 | Theravance Biopharma R&D Ip Llc | Naphthyridine and quinoline derivatives useful as alk5 inhibitors |
| CN114728941A (zh) | 2019-11-22 | 2022-07-08 | 施万生物制药研发Ip有限责任公司 | 作为alk5抑制剂的经取代的1,5-萘啶或喹啉 |
| KR102509625B1 (ko) * | 2022-03-25 | 2023-03-14 | 주식회사 메드팩토 | TGF-β 저해제의 합성에 유용한 중간체 및 이를 이용한 TGF-β 저해제 제조방법 |
| EP4717694A1 (en) * | 2023-05-22 | 2026-04-01 | Iregene Therapeutics Co., Ltd. | Pyrazolformyl piperazinone compound, pharmaceutical composition and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001163861A (ja) * | 1999-12-07 | 2001-06-19 | Nippon Soda Co Ltd | ジフェニルイミダゾール化合物および農園芸用殺菌剤 |
| NZ549003A (en) * | 2004-03-05 | 2009-07-31 | Taisho Pharmaceutical Co Ltd | Thiazole derivative as an ALK5 inhibitor |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| EP2108017A2 (en) * | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| SI2947072T1 (sl) * | 2008-03-17 | 2017-03-31 | Ambit Biosciences Corporation | 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni |
| AU2009227013B2 (en) * | 2008-03-21 | 2013-01-10 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| CN102131801B (zh) * | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
| WO2010078408A1 (en) * | 2008-12-30 | 2010-07-08 | Biogen Idec Ma Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| DK2731949T3 (en) | 2011-07-13 | 2018-06-14 | Tiumbio Co Ltd | 2-PYRIDYL-SUBSTITUTED IMIDAZOLS AS ALK5 AND / OR ALK4 INHIBITORS |
| JO3336B1 (ar) * | 2014-10-07 | 2019-03-13 | Lilly Co Eli | مركبات أمينو بيريديلوكسي بيرازول |
| EP3221318B1 (en) | 2014-11-21 | 2021-08-25 | Rigel Pharmaceuticals, Inc. | Fused imidazole derivatives as tgf-beta inhibitors |
| ES2789331T3 (es) | 2015-03-02 | 2020-10-26 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
| EP3527570A4 (en) | 2016-10-14 | 2020-04-15 | Jiangsu Hengrui Medicine Co., Ltd. | FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF |
| US11124509B2 (en) | 2017-03-23 | 2021-09-21 | Clavius Pharmaceuticals, LLC. | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment |
-
2018
- 2018-03-23 US US16/496,703 patent/US11124509B2/en active Active
- 2018-03-23 ES ES18823320T patent/ES3053505T3/es active Active
- 2018-03-23 EP EP18823320.9A patent/EP3600294B1/en active Active
- 2018-03-23 WO PCT/US2018/024133 patent/WO2019005241A1/en not_active Ceased
- 2018-03-23 JP JP2020501434A patent/JP2020512400A/ja active Pending
-
2021
- 2021-09-16 US US17/476,943 patent/US11845745B2/en active Active
-
2022
- 2022-12-22 JP JP2022205213A patent/JP2023052027A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019005241A1 (en) | 2019-01-03 |
| US20220073514A1 (en) | 2022-03-10 |
| US11124509B2 (en) | 2021-09-21 |
| JP2020512400A (ja) | 2020-04-23 |
| EP3600294A4 (en) | 2020-08-26 |
| EP3600294B1 (en) | 2025-09-03 |
| US11845745B2 (en) | 2023-12-19 |
| JP2023052027A (ja) | 2023-04-11 |
| US20200239462A1 (en) | 2020-07-30 |
| EP3600294A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3053505T3 (en) | Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment | |
| EP3902803B1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| BR112021012599A2 (pt) | Inibidores aza-heterobicíclicos de mat2a e métodos de uso para tratamento de câncer | |
| DK2137162T3 (en) | Organic compounds and their applications | |
| JP5992054B2 (ja) | ピラゾロピロリジン化合物 | |
| TW201833102A (zh) | 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法 | |
| AU2017319500A1 (en) | Inhibitors of cellular metabolic processes | |
| ES2687475T3 (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| BRPI0709082A2 (pt) | derivados de indazol substituìdos, sua fabricação e uso como agentes farmacêuticos | |
| ES2732437T3 (es) | Moduladores del receptor de CXCR7 | |
| EP1957078A2 (en) | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | |
| JP7147048B2 (ja) | Ｔｇｆ－ベータを阻害するための置換イミダゾールおよび処置方法 | |
| BR112013029935B1 (pt) | Compostos inibidores de diacilglicerol aciltransferase e composição farmacêutica compreende-os | |
| JP2019533650A (ja) | Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物 | |
| WO2023078319A1 (zh) | 一种可抑制il-17a的杂环化合物及其用途 | |
| JP2023520595A (ja) | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 | |
| WO2023150681A1 (en) | Inhibitors of raf kinases | |
| JP2025504495A (ja) | Ｒａｓシグナル伝達の調節因子としての縮合複素環式化合物 | |
| CN112759550A (zh) | 一种平滑受体拮抗剂 | |
| Abu-Hashem et al. | Recent advances in the chemistry of oxadiazepine derivatives: A significant leap in synthetic heterocycles and biological activity | |
| RU2804709C9 (ru) | Соединения для лечения некоторых лейкозов | |
| CN119019402A (zh) | 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途 | |
| OA20638A (en) | Aza-heterobicyclic inhibitors Of MAT2A and methods of use for treating cancer. | |
| HK40061678B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| HK40061678A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |